头孢美唑（先锋美他醇）治疗支气管肺炎的临床经验（作者译）
[Clinical experience of therapeutic use of cefmetazole (cefmetazon) or bronchopneumonia (author's transl)].
作者信息
Murao M, Terai T, Kirisawa T, Kon H, Moriyama Y, Hattori T
出版信息
Jpn J Antibiot. 1981 Jun;34(6):856-63.
PMID:6945446
Abstract
- Therapeutic effects of cefmetazole (cefmetazon, CMZ) were examined in 22 cases of bronchopneumonia. 2. Among the 22 cases, 17 cases (77%) showed better response than 'effective'. However, 10 cases (91%) showed better response than 'effective' if a daily of 4 g (11 cases) was taken into consideration. 3. No particular symptomatic side effect of CMZ was shown. Abnormality in such laboratory tests as transaminase (1 case of GOT, and 2 cases of GPT) and 1 case of alkaline phosphatase were observed, and the abnormality was ascribable to CMZ administration.
摘要
- 对22例支气管肺炎患者进行了头孢美唑（头孢米诺，CMZ）的治疗效果研究。2. 在这22例患者中，17例（77%）显示出比“有效”更好的反应。然而，如果考虑每日服用4g（11例）的情况，10例（91%）显示出比“有效”更好的反应。3. 未显示出CMZ有特殊的症状性副作用。观察到转氨酶（谷草转氨酶1例，谷丙转氨酶2例）和碱性磷酸酶1例等实验室检查异常，且该异常归因于CMZ给药。
Zotero 插件